Can cardiorespiratory fitness prior to hematopoietic cell transplantation be improved and will this limit morbidity and mortality following transplantation?
Does "goal-targeted" therapy (with adjustments/additional therapy, if certain "goals" are not achieved) improve quality of life, functional status, and survival in patients with pulmonary arterial hypertension? Trials of therapies for hepatopulmonary syndrome.
What are the prenatal determinants of adult pulmonary disease?
Does NIH intend to develop a new milestone-based grant system and introduce accountability with regards to reaching solid metrics and useful, quantifiable research goals and milestones? Does NIH intend to introduce a truly non-conflicted and independent grant review system, similar to the review system and accountability of the FDA, to increase research efficiency? Should the public be informed annually how effective ...more »
How do we identify new and more effective approaches to reduce the burden of venous disease and venous ulceration?
How to manage CVD risk factors in young adults
Inadequate sleep is associated with risk of obesity. Electronic media devices interfere with our ability to sleep well - they delay sleep, interrupt sleep, and affect sleep quality. However these devices are addictive and ubiquitous. Can we develop interventions to help people obtain adequate sleep?
Does bariatric surgery reduce the risk of MI, stroke, heart failure, and premature death in moderately obese adults?
Does the type of surgery matter?
Over 500,000 incident or recurrent venous thromboembolism (VTE) events occur annually in the US. Almost one-quarter of acute pulmonary embolism patients suffer sudden death. To improve survival, the occurrence of VTE must be reduced. However, the incidence of VTE has increased over the last 30 years. Moreover, near universal prophylaxis of patients hospitalized for surgery or for medical illness has not reduced hospitalization-associated ...more »
Better understand the consequences of drug interactions leading to QTc prolongation. About 1/3 of cardiac ICU patients develop QT prolongation and about 45% receive drugs that are possibly contributing to this problem. The full spectrum of contributors and causes, as well as the patient-centered and health-system-centered clinical outcomes, are not known.
What is the natural history of the best characterized ChILD disorders (surfactantrelated sequence variants, neuroendocrine cell hyperplasia of infancy (NEHI),pulmonary interstitial glycogenosis (PIG),idiopathic pulmonary hemosiderosis)?
Can cardiorespiratory fitness prior to hematopoietic cell transplantation be improved and will this limit morbidity and mortality following transplantation?